SLC5A2 and diabetes mellitus: More recently, new classes of anti-hyperglycemic drugs, such as sodium-glucose cotransporter type 2 inhibitors (SGLT-2 inhibitors) and glucagon-like peptide 1 receptor agonists (GLP1-R agonists), have been shown to reduce both the progression of albuminuria and the decline of GFR in patients with diabetes and high cardiovascular risk, even on top of available anti-albuminuric agents [9–11].